Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 469-475

  Verhoest, Grégory ^a,b   Patard, Jean Jacques ^a,b   Fergelot, Patricia ^a,b   Jouan, Florence ^a   Zerrouki, Salim ^b   Dreano, Stéphane ^a   Mottier, Stéphanie ^a   Rioux Leclercq, Nathalie ^a,b   Denis, Marc G ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; FEMALE; FROZEN SECTION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VHL GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; FEMALE; FROZEN SECTIONS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84862981594     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.07.005     Document Type: Article

References (34)

1. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication, and targeted molecular therapy. J Urol 2005, 173:1853-1862.
2. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295.
3. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
4. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
5. Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006, 49:633-643.
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
7. Yao M., Yoshida M., Kishida T., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569-1575.
8. Lidgren A., Hedberg Y., Grankvist K., et al. The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005, 11:1129-1135.
9. Brauch H., Weirich G., Brieger J., et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000, 60:1942-1948.
10. Schraml P., Struckmann K., Hatz F., et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196:186-193.
11. van Houwelingen K.P., van Dijk B.A., Hulsbergen-van de Kaa C.A., et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: Results from The Netherlands cohort study. BMC Cancer 2005, 5:57.
12. Kim J.H., Jung C.W., Cho Y.H., et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005, 13:859-864.
13. Banks R.E., Tirukonda P., Taylor C., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006, 66:2000-2011.
14. Patard J.J., Rioux-Leclercq N., Masson D., et al. Absence of VHL gene alteration and high VEGF expression are associated with tumor aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 2009, 101:1417-1424.
15. Sobin L.H., Wittekind C. TNM Classification of malignant tumors. UICC International Union Against Cancer 2003, 193-195. Wiley-Liss. 6th ed.
16. Patard J.J., Fergelot P., Karakiewicz P.I., et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008, 123:395-400.
17. Chen F., Kishida T., Duh F.M., et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995, 55:4804-4807.
18. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
19. Gallou C., Joly D., Mejean A., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999, 13:464-475.
20. Rini B.I., Jaeger E., Weinberg V., et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and von Hippel-Lindau gene status. BJU Int 2006, 98:756-762.
21. Ma X., Yang K., Lindblad P., et al. VHL gene alterations in renal cell carcinoma patients: Novel hotspot or founder mutations and linkage disequilibrium. Oncogene 2001, 20:5393-5400.
22. Hanage W.P., Aanensen D.M. Methods for data analysis. Methods Mol Biol 2009, 551:287-304.
23. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865. Discussion 865-6.
24. Gimenez-Bachs J.M., Salinas-Sanchez A.S., Sanchez-Sanchez F., et al. Determination of VHL gene mutations in sporadic renal cell carcinoma. Eur Urol 2006, 49:1051-1057.
25. Barnabas N., Amin M.B., Pindolia K., et al. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma. J Surg Oncol 2002, 80:52-60.
26. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34:58-68.
27. Lolkema M.P., Gervais M.L., Snijckers C.M., et al. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem 2005, 280:22205-22211.
28. Hofreiter M., Jaenicke V., Serre D., et al. DNA sequences from multiple amplifications reveal artifacts induced by cytosine deamination in ancient DNA. Nucleic Acids Res 2001, 29:4793-4799.
29. Marchetti A., Felicioni L., Buttitta F. Assessing EGFR mutations. N Engl J Med 2006, 354:526-528. author reply 526-8.
30. Williams C., Ponten F., Moberg C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999, 155:1467-1471.
31. Kenck C., Wilhelm M., Bugert P., et al. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996, 179:157-161.
32. Ferrer I., Armstrong J., Capellari S., et al. Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: A BrainNet Europe study. Brain Pathol 2007, 17:297-303.
33. Shi S.R., Cote R.J., Wu L., et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: Heating under the influence of pH. J Histochem Cytochem 2002, 50:1005-1011.
34. Coura R., Prolla J.C., Meurer L., et al. An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J Clin Pathol 2005, 58:894-895.